DK0831826T3 - Farmaceutisk præparat, som omfatter en proteaseinhibitor og et monoglycerid - Google Patents

Farmaceutisk præparat, som omfatter en proteaseinhibitor og et monoglycerid

Info

Publication number
DK0831826T3
DK0831826T3 DK96921929T DK96921929T DK0831826T3 DK 0831826 T3 DK0831826 T3 DK 0831826T3 DK 96921929 T DK96921929 T DK 96921929T DK 96921929 T DK96921929 T DK 96921929T DK 0831826 T3 DK0831826 T3 DK 0831826T3
Authority
DK
Denmark
Prior art keywords
monoglyceride
pharmaceutical composition
protease inhibitor
compositions
monoglycerides
Prior art date
Application number
DK96921929T
Other languages
Danish (da)
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0831826T3 publication Critical patent/DK0831826T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK96921929T 1995-06-06 1996-06-04 Farmaceutisk præparat, som omfatter en proteaseinhibitor og et monoglycerid DK0831826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (1)

Publication Number Publication Date
DK0831826T3 true DK0831826T3 (da) 2003-02-03

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921929T DK0831826T3 (da) 1995-06-06 1996-06-04 Farmaceutisk præparat, som omfatter en proteaseinhibitor og et monoglycerid

Country Status (27)

Country Link
EP (1) EP0831826B1 (de)
JP (1) JP3238412B2 (de)
CN (1) CN1092960C (de)
AT (1) ATE226075T1 (de)
AU (1) AU709796B2 (de)
BG (1) BG63711B1 (de)
BR (1) BR9610842A (de)
CA (1) CA2224125C (de)
CY (1) CY2373B1 (de)
CZ (1) CZ292192B6 (de)
DE (1) DE69624354T2 (de)
DK (1) DK0831826T3 (de)
EA (1) EA001413B1 (de)
ES (1) ES2182996T3 (de)
HK (1) HK1010136A1 (de)
HU (1) HU223899B1 (de)
IL (1) IL122353A0 (de)
IS (1) IS2661B (de)
MX (1) MX9709193A (de)
NO (1) NO324531B1 (de)
NZ (1) NZ311646A (de)
OA (1) OA10546A (de)
PL (1) PL184820B1 (de)
PT (1) PT831826E (de)
SK (1) SK282121B6 (de)
TR (1) TR199701541T1 (de)
WO (1) WO1996039142A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203648C2 (ru) 1997-07-29 2003-05-10 Фармация Энд Апджон Компани Самоэмульгирующаяся композиция для липофильных соединений
PT989851E (pt) 1997-07-29 2002-12-31 Upjohn Co Formulacao auto-emulsionante para compostos lipofilicos acidicos
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (de) 2008-04-08 2009-10-14 Universität Duisburg-Essen Verfahren zur Analyse der epigenetischen Lage des HtrA1 Gens in einer biologischen Probe
JP5718925B2 (ja) 2009-09-28 2015-05-13 インターシア セラピューティクス，インコーポレイティド 実質的な定常状態薬物送達の迅速な確立及び／又は停止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
JP3238412B2 (ja) 2001-12-17
PL184820B1 (pl) 2002-12-31
HUP9801905A2 (hu) 1999-05-28
SK282121B6 (sk) 2001-11-06
WO1996039142A1 (en) 1996-12-12
EA001413B1 (ru) 2001-02-26
CA2224125A1 (en) 1996-12-12
AU6300496A (en) 1996-12-24
CY2373B1 (en) 2004-06-04
DE69624354T2 (de) 2003-06-05
CN1186434A (zh) 1998-07-01
EP0831826A1 (de) 1998-04-01
HU223899B1 (hu) 2005-03-29
ATE226075T1 (de) 2002-11-15
DE69624354D1 (de) 2002-11-21
HUP9801905A3 (en) 2001-04-28
BG63711B1 (bg) 2002-10-31
HK1010136A1 (en) 1999-06-17
AU709796B2 (en) 1999-09-09
PL323860A1 (en) 1998-04-27
ES2182996T3 (es) 2003-03-16
NZ311646A (en) 2000-02-28
NO324531B1 (no) 2007-11-12
SK162797A3 (en) 1998-05-06
CZ380397A3 (cs) 1998-03-18
TR199701541T1 (xx) 1998-03-21
IS4627A (is) 1997-12-04
CA2224125C (en) 2004-09-28
IS2661B (is) 2010-08-15
NO975665D0 (no) 1997-12-05
OA10546A (en) 2002-05-29
JPH10507202A (ja) 1998-07-14
IL122353A0 (en) 1998-04-05
CZ292192B6 (cs) 2003-08-13
CN1092960C (zh) 2002-10-23
PT831826E (pt) 2003-02-28
BR9610842A (pt) 1999-07-13
NO975665L (no) 1998-02-05
EP0831826B1 (de) 2002-10-16
MX9709193A (es) 1998-03-31
BG102106A (en) 1998-08-31
EA199800023A1 (ru) 1998-08-27

Similar Documents

Publication Publication Date Title
DK0831826T3 (da) Farmaceutisk præparat, som omfatter en proteaseinhibitor og et monoglycerid
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
ZA9811830B (en) Prodrugs of aspartyl protease inhibitors.
BG103425A (en) Pharmaceutical composition
AU2012199A (en) Prodrugs of aspartyl protease inhibitors
NO20006717D0 (no) Proteaseinhibitorer
AU8875398A (en) 1-amino-7-isoquinoline derivatives as serine protease inhibitors
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
HRP20030983B1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
DK1023268T3 (da) Isoquinoliner som urokinaseinhibitorer.
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
FI962264A (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
NO975534L (no) Imidazo-£1,5|-pyridin-avledete serinproteaseinhibitorer
ZA969078B (en) Inhibitors of cysteine protease.
ECSP961778A (es) Composiciones que incrementan la biodisponibilidad de inhibidores de proteinasa